Biology
Confirm the subtype
ER, PR, HER2 and the complete pathology report shape the treatment pathway.
Breast Cancer Biology · HER2-Low
HER2-Low Breast Cancer Treatment and Testing
HER2-low is not the same as HER2-positive. It describes lower HER2 expression that may become treatment-relevant in advanced disease, making the exact IHC report important.
Answer first: HER2-low is not the same as HER2-positive. It describes lower HER2 expression that may become treatment-relevant in advanced disease, making the exact IHC report important.
Cancer Consultation
Speak With Our Cancer Patient Care Team
Tell us where you are in your cancer journey. Our Patient Care Team can answer questions and help determine the next step.
*
Required fields
Prefer to speak with someone now?
1-800-923-7878
✓
Stage 4 & advanced cancer patients welcome
✓
Out-of-state & international patients welcome
✓
Questions before scheduling are welcome
Understand the treatment question
The next step begins with accurate, current information.
Extent
Define where disease is present
Imaging, examination and symptoms clarify local, regional or distant disease.
History
Learn from prior response
What worked, what stopped working and what was tolerated all influence sequencing.
Treatment pathways
Use stage, biomarkers and goals to organize options.
Local treatment
Surgery and radiation may be relevant for primary, local or regional disease and for selected symptomatic metastatic sites.
Systemic treatment
Endocrine therapy, HER2-directed therapy, chemotherapy, immunotherapy, antibody-drug conjugates and mutation-directed treatment are considered according to subtype and setting.
Clinical trials and second opinions
A trial or pathology review may be especially useful when disease is uncommon, changing or resistant to prior treatment.
Natural and integrative care
A whole-person program built around the actual case.
Infusion therapies
IV vitamin C and glutathione
Physician-directed infusion support is considered with labs, medications, organ function and goals.
Botanicals
Mistletoe and polyphenols
Mistletoe, curcumin, resveratrol, silymarin and EGCG are discussed according to evidence level and formulation.
Immune context
Immune and NK-cell testing
Selected measurements may add context but are not a substitute for validated tumor biomarkers.
Emerging modality
Hydrogen inhalation
Molecular hydrogen is included as an emerging supportive modality with early human oncology research.
A Sunridge consultation
Turn information into a personalized next step.
- Physician review of records and prior treatment.
- Identification of missing pathology, biomarker or hereditary information.
- A natural and integrative program aligned with present health and goals.
- Travel planning for patients coming to Scottsdale.
Questions patients ask
Common questions
Can this page replace an individualized consultation?
No. It explains the decision framework; a real plan requires the complete records and clinical context.
Does Sunridge welcome complex or advanced cases?
Yes. Newly diagnosed, recurrent, metastatic and previously treated patients may request a physician review.
A closer look
How this topic fits the complete breast-cancer plan.
HER2-low generally refers to an IHC result of 1+ or 2+ without gene amplification. It is not a separate breast-cancer subtype in the same way as classic HER2-positive disease, and a tumor may also be hormone receptor-positive or triple-negative. The category became clinically important because some antibody-drug conjugates can deliver treatment to tumors with lower HER2 expression.
Testing deserves close attention. A result can vary between the original breast tumor and a metastasis, between laboratories, and even between samples from the same person. Patients should obtain the actual IHC and ISH reports rather than relying only on a summary that says “HER2-negative.” Sunridge reviews the complete pathology timeline and uses integrative care to address symptoms, strength, recovery and treatment tolerance alongside the oncology plan.
Prepare for a Sunridge review
The right records make the first conversation more useful.
Before contacting the Patient Care Team, gather every HER2 IHC and ISH report, the tested tissue site, prior HER2-directed exposure, current imaging and treatment history. A concise one-page chronology is often helpful: diagnosis date, stage, major test results, treatments received, response, side effects and the questions that matter most now.
Step 1
Send the records
The team can explain which reports and images are needed before a physician review.
Step 2
Define the priorities
List the treatment, symptom, recovery and quality-of-life questions you want the consultation to address.
Step 3
Plan the visit
Out-of-state and international patients can discuss timing, Scottsdale travel and which services require an in-person appointment.
Continue exploring
Explore Sunridge integrative therapies
Learn how these physician-directed therapies are evaluated within a personalized cancer-care program.
A personalized next step
Bring the complete breast-cancer story to the conversation.
Our Patient Care Team can explain which records to send, how a physician review works and what to expect when traveling to Scottsdale.
Request a consultationCall 1-800-923-7878This page is educational and does not provide a diagnosis or individualized treatment recommendation. Medication and integrative-treatment decisions require review of the complete case by qualified clinicians. Content reviewed August 2026.